Perform Multiparametric Prostate MRI Before Biopsy
In biopsy-naïve men with suspected prostate cancer, you should obtain a multiparametric MRI (mpMRI) first, before proceeding to biopsy. This is the current standard of care endorsed by major international guidelines and reduces unnecessary biopsies while improving detection of clinically significant cancer 1, 2.
Why MRI First: The Evidence
The 2026 EAU guidelines explicitly recommend mpMRI as the initial step after PSA/DRE raises suspicion for prostate cancer 1. This approach:
- Reduces unnecessary biopsies by identifying men with negative MRI (PI-RADS 1-2) who can safely avoid immediate biopsy
- Increases detection of clinically significant cancer (sensitivity 91% for ISUP Grade Group ≥2) while reducing overdiagnosis of insignificant disease 1
- Provides targeting information for more accurate biopsy when lesions are present
Multiple guideline organizations align on this approach 2:
- EAU: Strongest recommendation (Category 4) for mpMRI before first biopsy
- NCCN: Strong recommendation (Category 4)
- AUA: Moderate recommendation (Category 2)
- ACR: Moderate recommendation (Category 3)
The MRI-Based Diagnostic Algorithm
Step 1: Confirm PSA Elevation
- Repeat PSA if initially 3-10 ng/ml under standardized conditions (no ejaculation, manipulations, or UTIs for several weeks) 1
- Calculate PSA density (PSA-D = PSA/prostate volume)
Step 2: Obtain mpMRI
Proceed with mpMRI when:
- Confirmed PSA elevation and/or abnormal DRE
- PSA-D >0.09 ng/ml/cc (below this threshold, only 4% have clinically significant cancer) 1
Step 3: Act Based on PI-RADS Score
PI-RADS 1-2 (Negative MRI):
- Avoid immediate biopsy in most cases 1
- Consider PSA-D: if <0.09 ng/ml/cc, very low risk
- Implement surveillance with repeat PSA
- Only proceed to systematic biopsy if other high-risk features present (very high PSA, strong family history)
PI-RADS 3 (Equivocal):
- Combine with PSA-D for risk stratification 1
- Consider biopsy if PSA-D elevated (>0.15 ng/ml/cc)
- May observe with short-interval follow-up if PSA-D low
PI-RADS 4-5 (Positive MRI):
- Perform MRI-targeted biopsy (3-5 cores per lesion minimum) 1
- Add systematic biopsy of the contralateral lobe, even if MRI shows unilateral lesion 1, 2
- Use MRI/US fusion, cognitive targeting, or in-bore guidance
Critical Nuances and Pitfalls
When MRI May Be Less Effective
- Younger men (45-50 years): MRI may have reduced effectiveness in this age group 1
- In these cases, maintain lower threshold for proceeding to biopsy despite negative MRI
The Biparametric Option
- Biparametric MRI (without contrast) may be noninferior to full mpMRI if high-quality imaging with expert interpretation is available 1
- This reduces cost and scan time
Don't Skip Biopsy in High-Risk Scenarios
Even with negative MRI, proceed directly to systematic biopsy if:
- PSA >50 ng/ml with clinical stage T3-4 1
- Malignant-feeling prostate on DRE
- PSA >100 ng/ml (may even skip biopsy if bone scan positive and comorbidities preclude aggressive treatment) 1
Quality Matters
The accuracy of this MRI-first pathway depends heavily on:
- High-quality imaging with proper protocols
- Expert radiologist interpretation (significant inter-observer variability exists) 3
- If these aren't available at your institution, the benefit diminishes
The Counterargument (Why Some Oppose MRI First)
One dissenting view argues that MRI's negative predictive value (76-87%) is insufficient to safely omit biopsy, and its positive predictive value (27-44%) provides only incremental benefit over clinical risk calculators 4. However, this 2023 opinion piece contradicts the consensus of major 2025-2026 guidelines and doesn't account for the combined clinical-MRI risk stratification approach now recommended 1, 2.
After a Previous Negative Biopsy
If the patient already had a negative TRUS-guided biopsy, the recommendation for MRI becomes even stronger: